Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

NCT05174169 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

1912

Enrollment

OTHER

Sponsor class

Conditions

Stage III Colon Cancer

Interventions

DEVICE: Signatera test
DRUG: mFOLFOX6 3-6 month
DRUG: CAPOX 3 month
DRUG: mFOLFIRINOX
DRUG: mFOLFOX6 6 month
DRUG: CAPOX 6 month

Sponsor

NRG Oncology

Collaborators

[object Object]
[object Object]